{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:25:54Z","timestamp":1792031154256,"version":"4.4.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jcyt.2019.04.005","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T17:16:08Z","timestamp":1559322968000},"page":"769-781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies"],"prefix":"10.1016","volume":"21","author":[{"given":"Jun-Xia","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Long","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jcyt.2019.04.005_bib0001","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.beha.2018.03.001","article-title":"Off the shelf T cell therapies for hematologic malignancies","volume":"31","author":"McCreedy","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jcyt.2019.04.005_bib0002","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.trsl.2017.06.011","article-title":"Chimeric antigen receptor T-cells for B-cell malignancies","volume":"187","author":"Lichtman","year":"2017","journal-title":"Transl Res"},{"issue":"5","key":"10.1016\/j.jcyt.2019.04.005_bib0003","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/2040620715588916","article-title":"CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)","volume":"6","author":"Tasian","year":"2015","journal-title":"Ther Adv Hematol"},{"issue":"26","key":"10.1016\/j.jcyt.2019.04.005_bib0004","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jcyt.2019.04.005_bib0005","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1056\/NEJMe1714680","article-title":"A Milestone for CAR T Cells","volume":"377","author":"Tran","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcyt.2019.04.005_bib0006","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jcyt.2019.04.005_bib0007","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"5_suppl","key":"10.1016\/j.jcyt.2019.04.005_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.5_suppl.122","article-title":"Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R\/R aggressive B-NHL (TRANSCEND NHL 001 study)","volume":"36","author":"Siddiqi","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.jcyt.2019.04.005_bib0009","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/10428194.2012.715350","article-title":"Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials","volume":"54","author":"Xu","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.jcyt.2019.04.005_bib0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ejh.12602","article-title":"Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials","volume":"96","author":"Zhu","year":"2016","journal-title":"Eur J Haematol"},{"issue":"32","key":"10.1016\/j.jcyt.2019.04.005_bib0011","doi-asserted-by":"crossref","first-page":"33961","DOI":"10.18632\/oncotarget.5582","article-title":"Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.jcyt.2019.04.005_bib0012","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2217\/imt-2017-0062","article-title":"Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis","volume":"9","author":"Riaz","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jcyt.2019.04.005_bib0013","article-title":"Adoptive immunotherapy for B-cell malignancies using CD19-targeted chimeric antigen receptor T-cells: A systematic review of efficacy and safety","author":"Hao","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jcyt.2019.04.005_bib0014","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-018-3368-8","article-title":"The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review","author":"Jin","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2019.04.005_bib0015","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr Opin Biotechnol"},{"issue":"3","key":"10.1016\/j.jcyt.2019.04.005_bib0016","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1358\/dot.2018.54.3.2776625","article-title":"Axicabtagene ciloleucel for the treatment of relapsed\/refractory B-cell non-Hodgkin's lymphomas","volume":"54","author":"Sharma","year":"2018","journal-title":"Drugs Today (Barc)"},{"issue":"9","key":"10.1016\/j.jcyt.2019.04.005_bib0017","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jcyt.2019.04.005_bib0018","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.jcyt.2019.04.005_bib0019","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jcyt.2019.04.005_bib0020","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jcyt.2019.04.005_bib0021","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.jcyt.2019.04.005_bib0022","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"95","key":"10.1016\/j.jcyt.2019.04.005_bib0023","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.jcyt.2019.04.005_bib0024","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"issue":"177","key":"10.1016\/j.jcyt.2019.04.005_bib0025","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"issue":"16","key":"10.1016\/j.jcyt.2019.04.005_bib0026","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"224","key":"10.1016\/j.jcyt.2019.04.005_bib0027","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"9967","key":"10.1016\/j.jcyt.2019.04.005_bib0028","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.jcyt.2019.04.005_bib0029","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jcyt.2019.04.005_bib0030","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jcyt.2019.04.005_bib0031","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jcyt.2019.04.005_bib0032","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jcyt.2019.04.005_bib0033","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.jcyt.2019.04.005_bib0034","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jcyt.2019.04.005_bib0035","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1027469","article-title":"Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia","volume":"4","author":"Dai","year":"2015","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.jcyt.2019.04.005_bib0036","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jcyt.2019.04.005_bib0037","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jcyt.2019.04.005_bib0038","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jcyt.2019.04.005_bib0039","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"issue":"303","key":"10.1016\/j.jcyt.2019.04.005_bib0040","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"13","key":"10.1016\/j.jcyt.2019.04.005_bib0041","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1158\/1078-0432.CCR-16-1799","article-title":"Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed\/Refractory Acute Lymphocytic Leukemia","volume":"23","author":"Hu","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"355","key":"10.1016\/j.jcyt.2019.04.005_bib0042","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1016\/j.jcyt.2019.04.005_bib0043","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.jcyt.2019.04.005_bib0044","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jcyt.2019.04.005_bib0045","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.jcyt.2019.04.005_bib0046","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/bjh.14923","article-title":"Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation","volume":"179","author":"Chen","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jcyt.2019.04.005_bib0047","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ymthe.2018.01.022","article-title":"In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia","volume":"26","author":"Cheng","year":"2018","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.jcyt.2019.04.005_bib0048","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/ajh.25108","article-title":"Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"93","author":"Cao","year":"2018","journal-title":"Am J Hematol"},{"issue":"26","key":"10.1016\/j.jcyt.2019.04.005_bib0049","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcyt.2019.04.005_bib0050","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jcyt.2019.04.005_bib0051","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcyt.2019.04.005_bib0052","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00277-018-3246-4","article-title":"CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory\/relapsed acute lymphoblastic leukemia: results of a case-controlled study","volume":"97","author":"Wei","year":"2018","journal-title":"Ann Hematol"},{"issue":"25","key":"10.1016\/j.jcyt.2019.04.005_bib0053","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jcyt.2019.04.005_bib0054","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jcyt.2019.04.005_bib0055","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1186\/s12885-018-4817-4","article-title":"The efficacy and safety of anti-CD19\/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis","volume":"18","author":"Zhou","year":"2018","journal-title":"BMC Cancer"},{"issue":"6230","key":"10.1016\/j.jcyt.2019.04.005_bib0056","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jcyt.2019.04.005_bib0057","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.jcyt.2019.04.005_bib0058","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/imt-2016-0127","article-title":"Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review","volume":"9","author":"Anwer","year":"2017","journal-title":"Immunotherapy"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324919304074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324919304074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:38:31Z","timestamp":1761442711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324919304074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1465324919304074"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2019.04.005","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2019.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}